{"id":39634,"date":"2023-02-24T09:49:00","date_gmt":"2023-02-24T09:49:00","guid":{"rendered":"https:\/\/idafoundation.org\/?p=39634"},"modified":"2026-02-22T21:52:11","modified_gmt":"2026-02-22T21:52:11","slug":"invitation-to-bid-itb-on-behalf-of-stop-tb-gdf","status":"publish","type":"post","link":"https:\/\/idafoundation.org\/fr\/invitation-to-bid-itb-on-behalf-of-stop-tb-gdf\/","title":{"rendered":"Invitation to bid (ITB) on behalf of Stop TB\/GDF"},"content":{"rendered":"<p><strong>24 February 2023, Geneva, Switzerland<\/strong>&nbsp;&#8211; On behalf of Stop TB Partnership\u2019s Global Drug Facility (GDF), IDA Foundation (IDA), the GDF- contracted procurement agent, invites all eligible suppliers to submit bids (ITB) for:<\/p>\n\n\n\n<p><strong>ITB-IDA\/GDF-MED\/2023\/1<\/strong>, pretomanid tablets for the period until 31 December 2023.<strong><\/strong><\/p>\n\n\n\n<p><strong>UPDATE March 6:<\/strong>&nbsp;On request we provide clarification on the ITB-IDA\/GDF \u2013 MED\/2023\/1 &#8211; Pretomanid tablets. GDF\/IDA is looking forward to receive your bid as per the timeline stipulated in the ITB.&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/idafoundation.org\/wp-content\/uploads\/2026\/02\/QA_IDA-GDF-MED-2023-1_Final.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">QA IDA-GDF-MED-1<\/a><\/li>\n<\/ul>\n\n\n\n<p>The purpose of the ITBs is to select a panel of suppliers who will enter into a long-term agreement with IDA for pretomanid.<\/p>\n\n\n\n<p>The ITBs are open to bidders whose products have been deemed eligible for inclusion in the tender in compliance with GDF&#8217;s Quality Assurance policy and procedures (&nbsp;<a href=\"https:\/\/www.stoptb.org\/suppliers\/quality-assurance\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.stoptb.org\/suppliers\/quality-assurance<\/a>&nbsp;). A bid submitted for a product\/s for which the bidder has not received regulatory approval status in accordance with the GDF Quality Assurance policy and procedures shall not be considered for the ITB evaluation.<\/p>\n\n\n\n<p>All bids are subject to the Instructions to Bidders and other provisions, specifications and instructions as contained in this dossier.<\/p>\n\n\n\n<p>The ITB comprises of the following:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/idafoundation.org\/fr\/media\/wysiwyg\/GDF_ITB\/ITB2023\/ITB_document_IDA-GDF-MED-2023-1fin.pdf\/\" target=\"_blank\" rel=\"noreferrer noopener\">ITB Document<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/idafoundation.org\/fr\/media\/wysiwyg\/GDF_ITB\/ITB2023\/Annex_A_-_Financial_Bid_Response_Form.xlsx\/\" target=\"_blank\" rel=\"noreferrer noopener\">Annex A: Financial Bid Response Form<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/idafoundation.org\/fr\/media\/wysiwyg\/GDF_ITB\/ITB2023\/Annex_B_-_List_and_technical_specifications_of_requested_products.pdf\/\" target=\"_blank\" rel=\"noreferrer noopener\">Annex B: List and technical specifications of products requested<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/idafoundation.org\/fr\/media\/wysiwyg\/GDF_ITB\/ITB2023\/Annex_C-_List_of_priority_countries_for_TB_medicines_registration.pdf\/\" target=\"_blank\" rel=\"noreferrer noopener\">Annex C: List of priority countries for TB medicines registration<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/idafoundation.org\/fr\/media\/wysiwyg\/GDF_ITB\/ITB2023\/Annex_D_-_IDA_model_long-term_agreement_.pdf\/\" target=\"_blank\" rel=\"noreferrer noopener\">Annex D: IDA model long-term agreement (LTA)<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/idafoundation.org\/fr\/media\/wysiwyg\/GDF_ITB\/ITB2023\/Annex_E_-_Purchase_general_terms_and_conditions.pdf\/\" target=\"_blank\" rel=\"noreferrer noopener\">Annex E: IDA Purchase general terms and conditions<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/idafoundation.org\/fr\/media\/wysiwyg\/GDF_ITB\/ITB2023\/Annex_F_-_IDA_code_of_conduct.pdf\/\" target=\"_blank\" rel=\"noreferrer noopener\">Annex F: IDA code of conduct<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/idafoundation.org\/fr\/media\/wysiwyg\/GDF_ITB\/ITB2023\/Annex_G_-_GDF_access_to_supplier_information_for_WHO_PQP_and_ERP_assessed_TB_medicines.pdf\/\" target=\"_blank\" rel=\"noreferrer noopener\">Annex G: GDF access to supplier information for WHO PQP and ERP assessed TB medicines<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/idafoundation.org\/fr\/media\/wysiwyg\/GDF_ITB\/ITB2023\/Annex_H_-_Indicative_non-binding_estimated_quantities_of_products_requested.pdf\/\" target=\"_blank\" rel=\"noreferrer noopener\">Annex H: Indicative non-binding estimated quantities of products requested<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/idafoundation.org\/fr\/media\/wysiwyg\/GDF_ITB\/ITB2023\/Annex_I_-_GMSDs_address_list.pdf\/\" target=\"_blank\" rel=\"noreferrer noopener\">Annex I: GMSDs address list<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/idafoundation.org\/fr\/media\/wysiwyg\/GDF_ITB\/ITB2023\/Annex_J_-_Global_Drug_Facility_artwork_development_guidelines.pdf\/\" target=\"_blank\" rel=\"noreferrer noopener\">Annex J: Global Drug Facility packaging artwork development guidelines<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/idafoundation.org\/fr\/media\/wysiwyg\/GDF_ITB\/ITB2023\/Annex_K_-_Form_for_Requests_for_Clarifications_or_Complaints.docx\/\" target=\"_blank\" rel=\"noreferrer noopener\">Annex K: Form for Requests for Clarifications or Complaints after ITB awarding<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/idafoundation.org\/fr\/media\/wysiwyg\/GDF_ITB\/ITB2023\/Annex_L_-_CDP_Technical_Tender_Submission_-_Instructions_for_use.pdf\/\" target=\"_blank\" rel=\"noreferrer noopener\">Annex L: CDP Technical tender submission &#8211; Instructions for use<\/a><\/li>\n<\/ul>\n\n\n\n<p>You can also download all ITB-IDA\/GDF-MED\/2023\/1files in one .zip file by clicking&nbsp;<a href=\"http:\/\/www.stoptb.org\/assets\/documents\/gdf\/drugsupply\/pn6\/FLD.zip\" target=\"_blank\" rel=\"noreferrer noopener\">ici<\/a>.<\/p>\n\n\n\n<p>Bidders are requested to quote unit prices in accordance with the following delivery terms: EXW (Ex-Works), FCA (Free Carrier Alongside) and DAP India.<\/p>\n\n\n\n<p>Failure to adhere to the requirements of the ITB may lead to disqualification of the bidder and\/or rejection of the bid.<\/p>\n\n\n\n<p>Deadline for electronic submission of Technical and Financial Bids:<\/p>\n\n\n\n<p><strong>Friday 3 March 2023, 17h00 IST (India Standard Time) or 12h30 CET (Central European Time)<\/strong><\/p>\n\n\n\n<p>Public opening of the Financial Bids, accessible remotely, will take place on<\/p>\n\n\n\n<p><strong>Monday 6 March 2023 at 13h30 IST (India Standard Time) or 9h00 CET (Central European Time)<\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>24 February 2023, Geneva, Switzerland&nbsp;&#8211; On behalf of Stop TB Partnership\u2019s Global Drug Facility (GDF), IDA Foundation (IDA), the GDF- contracted procurement agent, invites all eligible suppliers to submit bids (ITB) for: ITB-IDA\/GDF-MED\/2023\/1, pretomanid tablets for the period until 31 December 2023. UPDATE March 6:&nbsp;On request we provide clarification on the ITB-IDA\/GDF \u2013 MED\/2023\/1 &#8211; [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":39635,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[197,196],"tags":[],"class_list":["post-39634","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-global-drug-facility","category-stop-tb-partnership"],"_links":{"self":[{"href":"https:\/\/idafoundation.org\/fr\/wp-json\/wp\/v2\/posts\/39634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idafoundation.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idafoundation.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idafoundation.org\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/idafoundation.org\/fr\/wp-json\/wp\/v2\/comments?post=39634"}],"version-history":[{"count":1,"href":"https:\/\/idafoundation.org\/fr\/wp-json\/wp\/v2\/posts\/39634\/revisions"}],"predecessor-version":[{"id":39637,"href":"https:\/\/idafoundation.org\/fr\/wp-json\/wp\/v2\/posts\/39634\/revisions\/39637"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idafoundation.org\/fr\/wp-json\/wp\/v2\/media\/39635"}],"wp:attachment":[{"href":"https:\/\/idafoundation.org\/fr\/wp-json\/wp\/v2\/media?parent=39634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idafoundation.org\/fr\/wp-json\/wp\/v2\/categories?post=39634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idafoundation.org\/fr\/wp-json\/wp\/v2\/tags?post=39634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}